Clovis?..................Good point................
Posted on 03/21/2014 7:41:57 AM PDT by RoosterRedux
Today’s biopharma industry has a richer and more exciting late stage pipeline of compelling new therapeutics than its had in years, drawing lots of enthusiasm from analysts and investors. Goldman Sachs (GS) recently published a report on the “10 drugs that could transform the industry” (Jan 2014), highlighting how many of these drugs have “game-changing commercial potential”, and that these drugs will help the industry “move beyond the cliff” of patent expiries. The GS healthcare team has put this “10 drug” snapshot out for the past few years and it’s always great list of inspiring therapeutics.
This year’s “top 10” won’t surprise many readers: it includes three immuno-oncology programs against PD-1/PD-L1, and an additional three against other cancer targets (BCL2, CDK4/6, and c-Met). The GS team also highlights another twenty drug programs that are “in mid/late stage clinical development that are either earlier in development or we have seen less clinical data” but are potentially high impact as well. Although I’m sure there are many programs of great interest that are missing from the list, these 30 programs represent a good proportion of the “cream of the crop”.
While the list itself is interesting, and each drug could be a blockbuster, I wanted to call attention to something the Goldman report and many others haven’t highlighted directly: the instrumental and essential role of smart business development deal-making underpinning these projects.
(Excerpt) Read more at forbes.com ...
Clovis.
Clovis?
Drug that is eradicating lung cancer. Maybe I am misspelling it, but it is AMAZING.
It’s about time cancer patients get access to some newer drugs based on immune-therapy. Big Pharma and the cancer centers have wrung the last dregs out of taxol and carboplatin drugs that came on line in the ‘60s and deliver around 30% effectiveness in actually curing cancer instead of forestalling death. It is time that all the genetic research begins bearing better results.
I am invested in IBB (the biotech etf) and follow it very closely.
Clovis?..................Good point................
“It is time that all the genetic research begins bearing better results.”
Sounds great.
Yet nature has her say and is the final arbiter.
If you are over 60 0bamaDeathCare will deny you access to these drugs.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.